ROSGQ (Rosetta Genomics) Current Ratio: 2.09 (As of Jun. 2017)


What is Rosetta Genomics Current Ratio?

Rosetta Genomics ROSGQ -99.00% Current Ratio is 2.09 as of Jun. 2017.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rosetta Genomics's current ratio for the quarter that ended in Jun. 2017 was 2.09.

Rosetta Genomics has a current ratio of 2.09. It generally indicates good short-term financial strength.

The historical rank and industry rank for Rosetta Genomics's Current Ratio or its related term are showing as below:

ROSGQ's Current Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.96
* Ranked among companies with meaningful Current Ratio only.

Rosetta Genomics  (OTCPK:ROSGQ) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Rosetta Genomics Current Ratio Related Terms


Rosetta Genomics Current Ratio Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Current Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.08 12.90 7.44 6.91 2.50

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.57 6.91 4.19 2.50 2.09

ROSGQ vs TEAR, IDTA, ABMC: Current Ratio Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics Current Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Current Ratio falls into.



Rosetta Genomics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Rosetta Genomics's Current Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Current Ratio (A: Dec. 2016 )=Total Current Assets (A: Dec. 2016 )/Total Current Liabilities (A: Dec. 2016 )
=9.513/3.804
=2.50

Rosetta Genomics's Current Ratio for the quarter that ended in Jun. 2017 is calculated as

Current Ratio (Q: Jun. 2017 )=Total Current Assets (Q: Jun. 2017 )/Total Current Liabilities (Q: Jun. 2017 )
=5.68/2.714
=2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 2.09 mean?
Rosetta Genomics (ROSGQ) has a Current Ratio of 2.09 as of Jun. 2017.
Is Rosetta Genomics' Current Ratio too high?
Rosetta Genomics' current Current Ratio is 2.09. The Medical Diagnostics & Research industry median Current Ratio is 1.96. Rosetta Genomics' value of 2.09 is 6.6% above this industry median.
How does Rosetta Genomics' Current Ratio compare to TEAR and IDTA?
Rosetta Genomics' Current Ratio of 2.09 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Current Ratio is 1.96. Rosetta Genomics' value of 2.09 is 6.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.96, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rosetta Genomics's current Current Ratio of 2.09 is 6.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Current Ratio is 2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Current Ratio of 2.09. The current Current Ratio is 2.09 and 6.6% above the Medical Diagnostics & Research industry median of 1.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Current Ratio is 2.09 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.